Press Release Archive
(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a discussion with David Simmons, President and General Manager, Established Products, and Jean-Michel Halfon, President and General Manager, Emerging Markets, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2009 at 8:35 a.m. Eastern Daylight Saving Time. To listen to the webcast, visit our web site at www.pfizer
(BUSINESS WIRE)--Pfizer Inc today announced that it has finalized a previously reported agreement in principle with the U.S. Department of Justice (DOJ) to settle an investigation regarding past off-label promotional practices related to Bextra, which Pfizer voluntarily withdrew from the market in 2005. The final agreement also resolves other DOJ investigations involving alleged past off-label promotional practices concerning Zyvox, Geodon
September 1, 2009 - Heading Back to School: Veterinarians Combine Stethoscopes with Microscopes
(BUSINESS WIRE)--Private practice isn’t for everyone, but for graduating veterinary students facing an average of $120,000 in debt, it often is the only logical choice. A new program—the Pfizer Animal Health–Morris Animal Foundation (MAF) Veterinary Fellowship for Advanced Study—gives current practitioners necessary financial support while they pursue a veterinary research career. The program commits a minimum of nearly $1.7
(BUSINESS WIRE)--For patients with established heart disease who were treated with a statin, 18 novel biomarkers including C-reactive protein (CRP) did not predict future cardiovascular events such as heart attack and stroke, according to results of an analysis presented today at the 2009 European Society of Cardiology Congress in Barcelona, Spain. By contrast, traditional lipid risk factors were RCELONA, Spain--strong predictors of cardiovascular
August 26, 2009 - Pfizer Inc Sponsors 7th Biennial U.S.–Africa Business Summit
(BUSINESS WIRE)--The Corporate Council on Africa (CCA) announced today that Pfizer Inc will sponsor the 7th Biennial U.S. – Africa Business Summit: Realizing the Investment Power of Africa, to be held at the Walter E. Washington Convention Center in Washington, D.C., September 29 – October 1, 2009. At a Pfizer-sponsored workshop titled Mobilizing Resources for Strengthening African Health Systems: A Case Study of Pfizer
(BUSINESS WIRE)--Pfizer Inc today announced that it has earned a score of 100 — the highest possible — in the 2010 Corporate Equality Index, which evaluates U.S.-based businesses on their treatment of lesbian, gay, bisexual and transgender (LGBT) employees, investors and consumers. The Corporate Equality Index — published annually by the Human Rights Campaign Foundation (HRCF), the largest LGBT advocacy organization
(BUSINESS WIRE)--Recognizing that patient participation in clinical trials is the key to progress in medical research, Pfizer Inc announced today that it has entered into a collaboration with Private Access, the innovator in privacy-enhanced search technology, to create a new online community aimed at increasing clinical trial awareness and participation. The site will be the first to focus on patient privacy rights to connect patients,
(BUSINESS WIRE)--President Bill Clinton announced two important and complementary agreements today to enable better, more affordable treatments for patients on second-line antiretroviral (ARV) therapy for HIV/AIDS in the developing world. For the first time, a second-line regimen of four ARVs will be available for under $500 annually. Additionally, the cost of a key drug for treating tuberculosis (TB) in patients using second-line ARVs has
July 30, 2009 - Pfizer, Kano State Reach Settlement Of Trovan Cases
(BUSINESS WIRE)--Pfizer Inc today announced it has reached agreement with the Kano State government in Nigeria to settle Kano State’s claims arising from the 1996 Trovan clinical study, which was conducted during Nigeria’s worst meningitis epidemic in history. Under the terms of the settlement, Kano State will dismiss both the civil and criminal Trovan-related cases it filed against the company and various individuals, and Pfizer
(BUSINESS WIRE)--NEW YORK
(BUSINESS WIRE)--Pfizer today announced a partnership with Fudan University to establish a graduate program in Clinical Data Management and Statistical Programming. This three year Masters Degree program, a first of its kind in China, is designed to develop qualified professionals to support clinical research which is rapidly increasing in China. “Pfizer is committed to creating and expanding our partnerships in China,
(BUSINESS WIRE)--Pfizer today announced a joint initiative with the Shanghai Institutes for Biological Sciences (SIBS) to support fundamental research in China. As part of the initiative, Pfizer China will provide US$500,000 each year over three years to fund health-related fundamental research projects at SIBS and its application to drug discovery and development programs in the country. This is the latest in a series of Pfizer
(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Chief Financial Officer, at the BMO Capital Markets 9th Annual Focus On Healthcare Conference on Wednesday, August 5, 2009 at 9:00 a.m. Eastern Daylight Saving Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “BMO Capital Markets Healthcare Conference
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts)
(BUSINESS WIRE)--At 96-week follow up, data from the MERIT ES analysis show that treatment-naïve HIV patients taking Celsentri/Selzentry (maraviroc), in combination with Combivir® (zidovudine/lamivudine) experienced comparable virologic suppression to undetectable levels and significantly greater increases in CD4 T-cell count through 96-weeks, compared to patients taking efavirenz in combination with zidovudine/ lamivudine. The data
(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) today announced that the European Commission (EC) has approved under the European Union (EU) Merger Regulation the company’s pending acquisition of Wyeth. The Commission's decision includes Pfizer’s commitment to divest certain animal health assets in the EU. “We are pleased to have achieved another significant milestone for the pending acquisition with the EC’s approval
(BUSINESS WIRE)--Pfizer Inc announced today results from two Phase 1 safety studies, one of PF-04360365, a humanized anti-amyloid monoclonal antibody (mAb), and another of dimebon (latrepirdine*) in combination with donepezil HCl tablets, in patients with Alzheimer’s disease.1,2 Based on the Phase 1 study results, PF-04360365 has advanced into Phase 2.3 Dimebon (latrepirdine), being co-developed by Pfizer and Medivation Inc., is in
(BUSINESS WIRE)--Pfizer Inc said today that it is disappointed by the Canadian Federal Court’s decision declaring invalid its patent covering amlodipine besylate, the active ingredient in Norvasc®, and that the company will appeal the decision to the Federal Court of Appeal of Canada. Pfizer's amlodipine besylate patent - Canadian Patent No. 1,321,393 - expires in 2010. The civil action was brought by Ratiopharm. Pfizer
(BUSINESS WIRE)--Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, and Pfizer Inc. (NYSE: PFE) today announced that they have entered into an Acquisition and License Agreement by which Graceway will acquire the worldwide commercial rights for three investigational dermatological molecules from Pfizer and the related transferred or licensed intellectual properties. “We are excited about the potential
(BUSINESS WIRE)--Pfizer Inc invites media and investors to listen to a teleconference related to CHANTIX at 1:15 PM US/EST on Wednesday, July 1. In addition to providing an update on CHANTIX, Pfizer scientists will answer press questions on the information provided. To listen to the teleconference, please use relevant dial-in number and passcode as listed below. Participant joining details
Pages
Press release archive foot note
Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.
Stay on top of Pfizer breaking news: Get News Alerts by RSS. 
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
 |
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page. |
Current Stock Price
| . |
. . |
| %Change | . | 52 Wk. High | . |
| Day High | . | 52 Wk. Low | . |
| Day Low | . | Mkt. Cap(Bil) | . |
| Open | . | ||
| Prev Close | . | Symbol | . |
| Vol. | . | Exchange | . |
Online Pfizer Press Kit
Our press kit provides information that might help you write stories or simply find out more about Pfizer.